Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, headquartered in The Woodlands, Texas, with an additional location in Bridgewater, New Jersey, is a biopharmaceutical company focused on developing and commercializing innovative treatments. The company is commercializing INPEFA® (sotagliflozin), a once-daily oral tablet approved on May 26, 2023, for reducing the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors. This approval was based on two Phase 3 cardiovascular outcomes studies, SOLOIST-WHF and SCORED, which demonstrated significant reductions in cardiovascular death and heart failure rehospitalizations by over 50% at 30 days compared to placebo after discharge. INPEFA® is one of three SGLT inhibitors currently indicated for heart failure. Lexicon Pharmaceuticals also has drug candidates targeting Diabetic Peripheral Neuropathic Pain (LX9211) and Type 1 Diabetes and Hypertrophic Cardiomyopathy (Sotagliflozin), both of which are wholly owned. Additionally, the company is evaluating a pre-clinical asset for obesity. Lexicon Pharmaceuticals employs a unique approach to gene science based on Nobel Prize-winning technology, having systematically studied the role and function of thousands of genes and identifying more than 100 precise protein targets. The company collaborates with other pharmaceutical and biotechnology companies, research institutes, and academic institutions. Lexicon Pharmaceuticals offers a comprehensive benefits package and provides equal employment opportunities and reasonable accommodations for qualified individuals with disabilities. The headquarters in The Woodlands is located in a forested enclave known for its excellent public and private schools, shopping, dining, and performing arts venues, just north of Houston’s Bush Intercontinental Airport.